Cassava Sciences, Inc. ($SAVA) Stock Forecast: Up 5.8% Today

What is Cassava Sciences, Inc.?

SAVA is a clinical-stage biopharmaceutical company focusing on treatments for Alzheimer's disease, with its lead drug candidate, simufilam, designed to tackle key disease-related issues.

Why is Cassava Sciences, Inc. going up?

SAVA stock is up 5.8% on Mar 17, 2026 14:00

• SAVA saw a significant uptrend after surpassing earnings expectations by $0.04 EPS, hinting at potential growth in its Alzheimer's drug pipeline.
• Despite legal challenges and the setback in a Phase 3 study for simufilam, investor outlook remains positive following the earnings outperformance.
• Increased institutional investment, notably with Marshall Wace LLP boosting its holdings in the company, may have bolstered investor confidence in SAVA's future.
• The company's rebranding to Filana Therapeutics, emphasizing therapies for central nervous system disorders, likely contributed to the positive investor sentiment and stock price surge.

SAVA Price Chart

SAVA Technical Analysis

SAVA News

Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA

Levi & Korsinsky, LLP reminds investors of Cassava Sciences, Inc. (SAVA) about a pending class action lawsuit. The lawsuit seeks to recover losses for investors who were adversely affected by alleged securities fraud between February 7, 2024, and November 24, 2024, after the company's leading drug candidate, simufilam, failed its Phase 3 study endpoints, causing an 83.76% stock price decline. The lead plaintiff deadline for the lawsuit is February 10, 2025.

https://www.marketscreener.com/quote/stock/FILANA-THERAPEUTICS-INC-56537199/news/Cassava-Sciences-Inc-Class-Action-Levi-Korsinsky-Reminds-Cassava-Sciences-Inc-Investors-of-th-48695867/

FLNA Stock Price and Chart — NASDAQ:FLNA

This article provides a detailed overview of Filana Therapeutics, Inc. (FLNA) stock, including its current price, historical performance, key financial statistics, and analyst ratings. It highlights the company's focus on developing drugs for Alzheimer's disease and includes frequently asked questions about its stock performance, earnings, and investment potential.

https://www.tradingview.com/symbols/NASDAQ-FLNA/

Cassava Sciences Posts Earnings, Beats Estimates

Cassava Sciences (NASDAQ:SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer's disease treatments, reported its first quarter earnings, posting a loss of $0.26 per share, which beat the consensus estimate of a $0.30 per share loss. The company is advancing its lead drug candidate, simufilam, which aims to restore normal function to a key scaffolding protein implicated in Alzheimer's disease. This positive earnings report is an encouraging sign for the progress of its Alzheimer's drug pipeline.

https://nationaltoday.com/us/tx/austin/news/2026/03/12/cassava-sciences-posts-earnings-beats-estimates/

Cassava Sciences (NASDAQ:SAVA) Posts Earnings Results, Beats Estimates By $0.04 EPS

Cassava Sciences (NASDAQ:SAVA) announced its earnings results, reporting an adjusted EPS of ($0.26), which surpassed the consensus estimate of ($0.30) by $0.04. Despite beating estimates, the company's shares remained flat at $2.38, and Wall Street maintains a "Reduce" rating with an average target price of $2.00. Institutional investment in Cassava Sciences has increased, with Marshall Wace LLP significantly raising its stake, bringing overall institutional ownership to 38.05%.

https://www.marketbeat.com/instant-alerts/cassava-sciences-nasdaqsava-posts-earnings-results-beats-estimates-by-004-eps-2026-03-12/

Filana Therapeutics (NASDAQ: FLNA) adopts new name and FLNA ticker

Cassava Sciences, Inc. has officially rebranded to Filana Therapeutics, Inc., effective March 10, 2026, and its common stock will now trade on the Nasdaq Capital Market under the new ticker symbol FLNA as of March 11, 2026. This change reflects the company's refined strategic focus on developing therapies that modulate the filamin A protein for central nervous system disorders like TSC-related epilepsy. The corporate website has also been updated to filanatx.com to align with the new identity and mission.

https://www.stocktitan.net/sec-filings/SAVA/8-k-cassava-sciences-inc-reports-material-event-60219774bffe.html

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 5.2% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.1% Today

Simon Property Group Inc. ($SPG) Stock Forecast: Down 1.5% Today

QuantumScape Corp. ($QS) Stock Forecast: Up 5.1% Today

Estee Lauder Companies Inc. (The) ($EL) Stock Forecast: Down 6.6% Today

Centene Corporation ($CNC) Stock Forecast: Down 5.1% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.6% Today

FMC Corporation ($FMC) Stock Forecast: Up 8.6% Today

Chegg Inc. ($CHGG) Stock Forecast: Up 7.6% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.6% Today

Cassava Sciences, Inc. Price History

14.00.2026 - SAVA Stock was up 5.6%

• Despite disappointing Phase 3 trial results for simufilam in Alzheimer’s disease, Cassava Sciences experienced a strong bullish movement.
• The announcement of pivoting towards developing simufilam for TSC-related epilepsy might have sparked investor optimism and interest in the company's future prospects.
• The increased volume of call options being bought, along with insider buying and institutional investment, could indicate a belief in the potential success of the new development direction despite the challenges faced by the company.
• The stock price increase could also be influenced by short-term speculative trading rather than a reflection of the company's long-term outlook.

16.02.2026 - SAVA Stock was up 5.8%

• Despite facing financial difficulties and receiving a "Hold" rating from analysts, the transition from Cassava Sciences to Filana Therapeutics and the company's strategic pivot towards filamin A-modulating therapies for central nervous system disorders such as TSC-related epilepsy seem to have captured investor attention, resulting in the stock's positive performance.
• Beating earnings expectations by $0.04 EPS may have also contributed to the optimistic market sentiment, signaling potential growth and resilience despite prior challenges.
• While reminders of pending class action lawsuits could have initially caused uncertainty, the overall market response indicates that investors are more focused on the company's future prospects and strategic direction rather than past hurdles.
• The surge in institutional investment, notably Marshall Wace LLP increasing its stake substantially, further bolsters the favorable outlook for Filana Therapeutics, showcasing rising institutional confidence in the company's potential.

24.01.2026 - SAVA Stock was up 10.7%

• The closure of the investigation into Cassava Sciences has brought relief to investors, leading to a bullish movement in the stock.
• The decision to scrap the development of simufilam for Alzheimer's and focus on tuberous sclerosis complex-related epilepsy may have positively influenced market sentiment.
• Resolving legal uncertainties and moving forward with a new therapeutic direction could be seen as a strategic and positive development for Cassava Sciences, driving investor confidence and pushing the stock price higher.

21.00.2026 - SAVA Stock was up 6.3%

• The upward movement in SAVA today may be linked to positive developments or speculation surrounding the advancement of its Alzheimer's drug, simufilam.
• Investors could be reacting to recent updates on the clinical trials or regulatory approval process, leading to a rise in the stock price.
• The risky nature of Cassava Sciences might also be attracting investors seeking potential high returns despite the volatility.

06.01.2026 - SAVA Stock was up 5.5%

• The positive movement in SAVA stock today could be linked to an upgrade from a prominent financial analysis source, potentially boosting investor confidence.
• A notable rise in CEO Richard Barry's ownership stake by more than 10% might reflect optimism and faith in the company's future.
• Diverse analyst viewpoints aside, the recent insider activity and potential advancements in Alzheimer's disease treatments may have influenced the upward trend in the stock value.

16.00.2026 - SAVA Stock was down 5.2%

• Cassava Sciences unveiled the outcomes of its Phase 3 clinical trials for simufilam targeting Alzheimer's disease, indicating that the drug fell short of its primary, secondary, and exploratory objectives. As a result, the Alzheimer's program was terminated.
• Despite this setback, Cassava Sciences is redirecting its efforts towards developing simufilam for epilepsy related to tuberous sclerosis complex (TSC), although it is encountering obstacles like a recent FDA clinical hold on its proposed trial for this new use.
• The company is grappling with financial difficulties, marked by substantial net losses and a settlement for a securities class action lawsuit. These challenges likely contributed to the recent market downturn as investors respond to the uncertainties surrounding Cassava Sciences' future in the pharmaceutical domain.

13.02.2026 - SAVA Stock was up 5.8%

• The company surpassed earnings estimates by $0.04 EPS, yet the stock price remained at $2.38, with the market showing a subdued reaction to this positive performance.
• Filana Therapeutics (FLNA)'s rebranding and strategic shift towards addressing high-unmet-need epilepsy conditions potentially attracted investor attention, influencing the stock's upward trend.
• Increased institutional investment, including a notable stake raise by Marshall Wace LLP, likely enhanced investor confidence in the company's new focus and future outlook, contributing to the positive trajectory of the stock.
• Despite facing financial hurdles and mixed analyst evaluations, the market appears cautiously upbeat about Filana Therapeutics (FLNA), as evidenced by today's bullish movement.

05.02.2026 - SAVA Stock was down 5.6%

• Analysts expect Cassava Sciences (SAVA) to report a quarterly loss per share, indicating a negative forecast.
• The company's financial statements display worrisome metrics including a negative EBITDA, free cash flow, and net income, highlighting financial challenges.
• Recent SEC filings have disclosed significant events like an FDA clinical hold on a trial, potentially impacting investor trust in the company's pipeline.
• The anticipated earnings loss mirrors the prevailing negative sentiment surrounding the stock, influencing today's bearish market activity.

17.02.2026 - SAVA Stock was up 5.8%

• SAVA saw a significant uptrend after surpassing earnings expectations by $0.04 EPS, hinting at potential growth in its Alzheimer's drug pipeline.
• Despite legal challenges and the setback in a Phase 3 study for simufilam, investor outlook remains positive following the earnings outperformance.
• Increased institutional investment, notably with Marshall Wace LLP boosting its holdings in the company, may have bolstered investor confidence in SAVA's future.
• The company's rebranding to Filana Therapeutics, emphasizing therapies for central nervous system disorders, likely contributed to the positive investor sentiment and stock price surge.

30.11.2025 - SAVA Stock was down 6.3%

• The bearish movement observed in SAVA stock today might be linked to the resolution of a consolidated securities class action lawsuit for $31.25 million. While not admitting fault, this settlement could have raised concerns among investors regarding the company's corporate governance and legal matters.
• The recent FDA clinical hold on Cassava Sciences' proposed simufilam clinical trial for TSC-related epilepsy may have also contributed to the negative sentiment. Investors could be anxious about the delays in advancing this significant drug candidate.
• Shareholder engagement and discussions surrounding potential corporate governance adjustments, as brought up by Halper Sadeh LLC, may be heightening the uncertainty surrounding the stock. Investors might be exercising caution concerning the company's upcoming policies and decision-making procedures.
• Despite the obstacles, the resolution of the investor lawsuit and the company's concentration on advancing simufilam for TSC-related epilepsy could provide some hope for the future. Nevertheless, the stock could face fluctuations as investors analyze the consequences of these recent occurrences.

26.00.2026 - SAVA Stock was down 5.4%

• SAVA was downgraded to a "sell" rating, potentially sparking a bearish sentiment among investors.
• Despite surpassing earnings estimates, the overall consensus rating remains "Reduce" with a low average price target of $2.00, possibly contributing to the prevailing negative sentiment.
• The mixed signals from the earnings performance versus the "sell" rating could have resulted in uncertainty, fueling the significant bearish trend observed in SAVA's stock price.

11.02.2026 - SAVA Stock was up 5.8%

• The bullish movement in SAVA stock today could be attributed to the company's strategic rebranding as Filana Therapeutics, Inc., signaling a shift towards a more focused approach in developing treatments for high-unmet-need epilepsy indications.
• Investors may view this rebranding as a positive step towards addressing specific medical needs, potentially attracting increased investor interest in the company's future prospects.
• The market's positive reaction to the name change and refined strategic focus suggests that investors are optimistic about Filana Therapeutics' potential in the field of central nervous system disorders, particularly TSC-related epilepsy.